TriSalus Life Sciences (TLSIW) Operating Expenses (2021 - 2026)

TriSalus Life Sciences has reported Operating Expenses for 6 years, with the latest figure at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 4.84% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $36.8 million (up 10.08% YoY), and the FY2025 full-year result was $36.4 million, up 2.16% from the prior year.
• Operating Expenses for Q1 2026 stood at $8.7 million, up from $6.7 million in the prior quarter.
• The five-year high for Operating Expenses was $18.5 million in Q3 2023, with the low at $288273.0 in Q2 2022.
• Historically, Operating Expenses has averaged $9.0 million across 5 years, with a median of $8.9 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses tumbled 63.23% — and 2023, when it surged 3987.1%.
• TriSalus Life Sciences' Operating Expenses stood at $10.3 million in 2022, then soared by 33.49% to $13.8 million in 2023, then sank by 44.75% to $7.6 million in 2024, then retreated by 11.48% to $6.7 million in 2025, then gained by 28.57% to $8.7 million in 2026.
• The last three Operating Expenses figures came in at $8.7 million (Q1 2026), $6.7 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.